Valuation: Aligos Therapeutics, Inc.

Market Cap 3Cr 2.68Cr 2.47Cr 2.24Cr 4.18Cr 284.6Cr 4.26Cr 29Cr 12Cr 149.71Cr 11Cr 11Cr 472.13Cr P/E 2026 *
-0.74x
P/E 2027 * -0.89x
Enterprise Value -36.32L -32.53L -29.92L -27.11L -50.68L -34Cr -51.63L -3.57Cr -1.43Cr -18Cr -1.36Cr -1.33Cr -57Cr EV / Sales 2026 *
-0.1x
EV / Sales 2027 * -57.7x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day-4.57%
1 week+0.42%
1 month-12.73%
3 months+13.48%
6 months-21.18%
Current year-48.50%
1 week 4.63
Extreme 4.63
5.38
1 month 4.55
Extreme 4.55
5.65
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
09/03/26 Free

Chief Technology Officer

23,310 0.4354%
09/03/26 Free

Controller/Auditor

9,450 0.1765%
09/03/26 Free

Chief Executive Officer

1,05,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
-4.57%+0.42%-41.82%-74.40% 3Cr
-0.62%-1.87%+42.87%+67.17% 6.38TCr
-1.31%+2.05%+12.17%+71.82% 5.64TCr
+0.31%+1.92%+19.99%+102.19% 5.46TCr
-2.81%-4.31%+23.50%+48.51% 4.41TCr
-0.33%-1.93%+19.28%+104.26% 4.21TCr
+0.55%+2.31%+225.14%+840.10% 4.1TCr
-3.90%+26.35%+100.86%+89.72% 3.49TCr
+1.22%-1.44%+14.57%+47.05% 3.28TCr
+0.89%+20.55%-40.62%+350.50% 2.47TCr
Average -1.05%+6.83%+37.59%+164.69% 3.94TCr
Weighted average by Cap. -0.72%+5.44%+47.13%+172.98%

Financials

2026 *2027 *
Net sales 3.6Cr 3.22Cr 2.97Cr 2.69Cr 5.02Cr 341.75Cr 5.12Cr 35Cr 14Cr 179.77Cr 14Cr 13Cr 566.94Cr 46.5L 41.65L 38.31L 34.71L 64.88L 44Cr 66.1L 4.57Cr 1.83Cr 23Cr 1.75Cr 1.71Cr 73Cr
Net income -7.93Cr -7.11Cr -6.54Cr -5.92Cr -11Cr -753.37Cr -11Cr -78Cr -31Cr -396.29Cr -30Cr -29Cr -1.25TCr -12Cr -11Cr -10Cr -9.32Cr -17Cr -1.19TCr -18Cr -122.69Cr -49Cr -623.77Cr -47Cr -46Cr -1.97TCr
Net Debt -3.36Cr -3.01Cr -2.77Cr -2.51Cr -4.69Cr -319.09Cr -4.78Cr -33Cr -13Cr -167.85Cr -13Cr -12Cr -529.34Cr -30Cr -27Cr -25Cr -22Cr -42Cr -2.83TCr -42Cr -292.93Cr -117.59Cr -1.49TCr -111.9Cr -109.52Cr -4.7TCr
Projected Income Statement - Annual - Aligos Therapeutics, Inc.
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
30/26/30 $4.800 -4.57% 23,846
29/26/29 $5.030 -2.71% 47,200
28/26/28 $5.170 +9.07% 23,453
27/26/27 $4.740 +1.94% 9,528
26/26/26 $4.650 -2.72% 33,001
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aligos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.800USD
Average target price
52.38USD
Spread / Average Target
+991.15%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aligos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALGS Stock